FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Fate Therapeutics
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Nurix Therapeutics, Inc.
University of Chicago
DEKA Biosciences
AstraZeneca
Shanghai Jiao Tong University School of Medicine
University of Chicago
Novartis
AIDS Malignancy Consortium
Memorial Sloan Kettering Cancer Center
Genentech, Inc.
Massachusetts General Hospital
University of Kentucky
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Rutgers, The State University of New Jersey
Case Comprehensive Cancer Center